Tag: mitral valve

4C Medical’s Novel Mitral Regurgitation Therapy to be Highlighted at CRT 2018 Meeting

BROOKLYN PARK, Minn., March 1, 2018 /PRNewswire/ — 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) will be highlighted in two presentations at the Cardiovascular Research Technologies (CRT) meeting held March 3-6, 2018 in Washington, DC.  4C Medical is developing the first MR […]

Boston Scientific Announces Investment and Acquisition Option Agreement with Millipede, Inc.

MARLBOROUGH, Mass., Jan. 24, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR). Under the terms of the agreements, Boston Scientific has purchased […]

HighLife Appoints Jose Calle Gordo as Chairman of the Board

PARIS–(BUSINESS WIRE)–HighLife SAS, a medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment of Mr. Jose (“Pepe”) Calle Gordo as Chairman of its Board of Directors. Pepe brings 30 years of broad business and management experience in the medical device industry, having served […]

Edwards Lifescience Scoops Up Harpoon Medical for $100M

IRVINE, Calif., Dec. 6, 2017 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced the acquisition of Harpoon Medical, a privately held medical technology company pioneering beating-heart repair for degenerative mitral regurgitation (DMR). Edwards announced a structured upfront investment in Harpoon in 2015, with […]

Medtronic Shows Off Early Intrepid TMVR Data

DUBLIN and DENVER – November 1, 2017 – Medtronic (NYSE:MDT) today presented positive data for its self-expanding Intrepid(TM) transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation. Presented as a First Report Investigation at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting and simultaneously published in the Journal of the American College of Cardiology (JACC), data […]

Early-Stage Medtech HighLife Nabs $14M for Transcatheter Mitral Valve Replacement

PARIS–(BUSINESS WIRE)– HighLife, an early-stage medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the closing of a €12.3 million investment round led by Sofinnova Partners which becomes the main investor in the company. HighLife had previously secured financing from LivaNova PLC, which also participated […]

First Patient Treated in Medtronic’s Landmark Transcatheter Mitral Valve Replacement (TMVR) Pivotal Trial

DUBLIN – October 23, 2017 – Medtronic (NYSE:MDT) today announced the first patient implant in the APOLLO Trial – the pivotal trial designed to evaluate the Intrepid(TM) TMVR system following receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA). As the first-ever pivotal trial for transcatheter mitral valve replacement therapy, the […]

Neovasc Provides Tiara™ Clinical Update

VANCOUVER, Sept. 12, 2017 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation (“MR”), one of the most prevalent valvular heart diseases in western countries.  MR is often severe […]

SHS invests in innovative heart valve-repair start-up CoreMedic

Tuebingen, 27. July 2017. SHS Gesellschaft für Beteiligungsmanagement is investing in CoreMedic, a start-up developing innovative, transfemoral repair systems to treat heart valve malfunctions. SHS is investing from its fourth fund generation to finance CoreMedic’s further growth and the clinical application of its innovative products. Mitral heart valve regurgitation (MR) is one of the most […]

4C Medical’s Novel Mitral Regurgitation Therapy Highlighted at CVI 2017 Innovation Summit

NEWS PROVIDED BY 4C Medical Technologies, Inc. 07:04 ET BROOKLYN PARK, Minn., Aug. 3, 2017 /PRNewswire/ — 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive therapies for structural heart disease, today announced that its medical device therapy for mitral regurgitation (MR) was featured in the Innovation Summit at Cardiovascular Innovations (CVI) 2017 held August 2, 2017in Denver, CO. 4C […]